Pre-made Polatuzumab benchmark antibody ( Whole mAb ADC, anti-CD79B therapeutic antibody, Anti-AGM6/B29/IGB Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Polatuzumab vedotin contains a monoclonal antibody that binds to a protein called CD79B, which is found on B cells (a type of white blood cell) and some lymphoma cells. It also contains an anticancer drug, which may help kill cancer cells. Polatuzumab vedotin is a type of antibody-drug conjugate. Also called Polivy.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-449-1mg	1mg	4635
GMP-Bios-ab-449-10mg	10mg	Inquiry
GMP-Bios-ab-449-100mg	100mg	Inquiry
GMP-Bios-ab-449-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody
INN Name	Polatuzumab
Target	CD79B
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Chugai Pharmaceutical;Genentech;Roche
Conditions Approved	Diffuse large B cell lymphoma
Conditions Active	Non-Hodgkin's lymphoma;Follicular lymphoma
Conditions Discontinued	Chronic lymphocytic leukaemia
Development Tech	na